北京招聘

Responsibility

1. Contribute the activity to selection, negotiation with and supervision of CROs (e.g. preclinical DMPK enabling package, GLP TK bioanalysis)
2. Write and/or organize regulatory documents to support IND filing in China and US, ensure an adequate IND/First in human enabling packages
3. Acts as DMPK presentative in preclinical and clinical project teams to be involved in study design, strategic inputs for drug development, data interpretation

Candidate qualifications

1. Fluent in spoken and good in written English
2. PhD with at least 2-year experience in pharma or major China CROs
3. Basic knowledge of regulatory guidelines related to PK and PD studies and evaluations
4. Good communication skills, able to communicate effectively with colleagues and external contacts
5. Team player; prior experience working within a matrix environment preferred. Is able to do problem solving with “can do” attitude;
6. Good and hands-on experience in drug metabolism, transporter related experiments, and DDI risk assessment to satisfy regulatory requirements;
7. Functional understanding of the application of tools such as, but not limited to Phoenix WinNonLin (or other similar PK analysis tools);

    迪哲医药的前身为阿斯利康亚洲及新兴市场创新研发中心，设立于中国上海，是阿斯利康全球四个研发中心之一（另三个中心分别位于英国剑桥、瑞典哥德堡、美国盖瑟斯堡）；是国际一流、高产出的创新药研发机构，拥有全球领先的转化医学和新药分子设计与筛选技术平台；在恶性肿瘤、自身免疫性疾病、肾病等重大疾病的新药研究方面积累了丰富经验。
    迪哲医药，于2017年10月独立运营，是一家研发驱动型生物医药企业，致力于全球创新药物（First-in-class/ Best-in-class）探索、研发以及商业化。
    详情请点击公司官方网站：**************************/

Dizal Pharma
On Nov. 27th, 2017, through a joint venture between AstraZeneca and China Advanced Manufacturing Fund, Dizal Pharma was co-constructed as a world-leading innovative bio-pharmaceutical enterprise. As a new, unique mode of cooperation between SDIC Fund Management Company Ltd. and worldwide privileged research resources in the field of biological pharmacy, Dizal Pharma can not only accelerate the launch and listing of global new drugs in China, bring Chinese patients access to the latest drugs found across the world at once and thus raise the clinical benefits of patients; At the same time, we also take advantages of the global privileged innovative resources, increase China’s core competitive power in the innovation of new drugs, step in the leading branch of international research and development of new drugs and push China into the role of causing both huge and powerful influence in pharmacy industry.
As a new-style joint venture company, besides the project of the transfer of AstraZeneca’s patents, Dizal Pharma also develops the innovation and creation of global First-in-Class drugs.
The R&D (Research and Development) team of Dizal Pharma was AstraZeneca Asia and Emerging Market Research Center. As one of AstraZeneca’s first four R&D centers across the world, it dedicated to analyze the potential scientific mechanism of those most common diseases in Asia and fulfill the particular medical needs of Asian patients. It was one of the few R&D centers established by transnational pharmacy enterprises in China which had the ability to actually research, develop and produce micro-molecular new drugs, the ability to develop produce new drugs independently and completely, and the first-class medical platform in the world.